Patents by Inventor Yushi Saino

Yushi Saino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding human placental coagulation inhibitor (PCI)
    Patent number: 5591633
    Abstract: A polypeptide having a specific amino acid sequence is described. Also described are a novel DNA coding the polypeptide, a recombinant plasmid containing the DNA, a transformant containing the recombinant plasmid, an anticoagulant containing the polypeptide as an effective ingredient, and a process for the production of the polypeptide.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: January 7, 1997
    Assignee: Kowa Co., Ltd.
    Inventors: Yushi Saino, Akio Iwasaki, Makoto Suda
  • Therapeutic agent for skin or corneal disease
    Patent number: 5360789
    Abstract: A therapeutic agent for skin or corneal diseases containing CPB-I (calphobindin-I) or recombinant CPB-I as the active ingredient. The CPB-I or recombinant CPB-I have excellent activities in promoting regeneration of granulation tissue, migration of corneal endothelial and epithelial cells, etc., and lowering PKC activity. Because the agent has an action mechanism different from that of the conventional agent, it can be used together with the conventional agent to enhance the therapeutic effect, thus being remarkably useful for treating all sorts of the skin and corneal diseases, in particular, wound and psoriasis.
    Type: Grant
    Filed: May 20, 1993
    Date of Patent: November 1, 1994
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Nakao, Takao Nagoya, Yushi Saino
  • DNA encoding a human thrombomodulin having a modified glycosaminoglycan (GAG) binding site
    Patent number: 5354664
    Abstract: Thrombin-binding substances capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively on a large scale.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: October 11, 1994
    Assignee: Kowa Co., Ltd.
    Inventors: Takeshi Doi, Akio Iwasaki, Yushi Saino, Shigeru Kimura, Masao Ohkuchi
  • Placenta-derived coagulation inhibitor
    Patent number: 5290915
    Abstract: A monoclonal antibody specific to a human placenta-derived coagulation inhibitor is disclosed. The antibody is produced by culturing a hybridoma which secretes it. A human placenta-derived coagulation inhibitor can be purified by using the monoclonal antibody as an immunoadsorbent. The human placenta-derived coagulation inhibitor can be immunologically assayed by using the monoclonal antibodies.
    Type: Grant
    Filed: January 13, 1992
    Date of Patent: March 1, 1994
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Nakao, Takao Nagoya, Yushi Saino, Masahiro Maki, Hideo Tani
  • Human urinary thrombomodulin with a modified glycosaminoglycan (GAG) binding site
    Patent number: 5273962
    Abstract: Recombinant thrombin-binding substances, derived from thrombomodulin by modification of the c-terminal glycosaminoglycan (GAG) binding site and capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively in a large scale.
    Type: Grant
    Filed: February 8, 1993
    Date of Patent: December 28, 1993
    Assignee: Kowa Co., Ltd.
    Inventors: Takeshi Doi, Akio Iwasaki, Yushi Saino, Shigeru Kimura, Masao Ohkuchi
  • Anti-PCI monoclonal antibody
    Patent number: 5192694
    Abstract: A monoclonal antibody specific to a human placenta-derived coagulation inhibitor is disclosed. The antibody is produced by culturing a hybridoma which secretes it. A human placenta-derived coagulation inhibitor can be purified by using the monoclonal antibody as an immunoadsorbent. The human placenta-derived coagulation inhibitor can be immunologically assayed by using the monoclonal antibodies.
    Type: Grant
    Filed: November 5, 1987
    Date of Patent: March 9, 1993
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Nakao, Takao Nagoya, Yushi Saino
  • Method of treatment using an anticoagulant polypeptide
    Patent number: 5179081
    Abstract: A polypeptide having an amino acid sequence as shown in FIG. 1 and its preparation method are disclosed. A DNA fragment capable of coding CPBII polypeptide (human placenta-derived coagulation inhibitor) is first obtained from the human placental cDNA library by using a CPBII-specific antibody as a probe. Then, microorganism cells are transformed by the use of a recombinant plasmid incorporated with the DNA fragment, allowing the resultant transformant to express the CPBII gene, to finally obtain a CPBII-like polypeptide. The polypeptide of this invention exhibits strong anticoagulation activities, and useful for an active component of anticoagulation medicines and preventin in vivo blood coagulation.
    Type: Grant
    Filed: May 1, 1991
    Date of Patent: January 12, 1993
    Assignee: Kowa Co., Ltd.
    Inventors: Akio Iwasaki, Makoto Suda, Yushi Saino